Sujatha Nallapareddy, MD
Hematology & Oncology · Aurora, CONPI 1164578779
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.1% of the total. 2025 is the largest year on record at $33,457, 6.0 times the $5,609 reported in 2019. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $408.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$37K
- AstraZeneca$12K
- Ipsen Biopharmaceuticals, Inc$10K
- Lilly USA, LLC$9K
- Array Biopharma Inc$8K
- Seagen Inc.$6K
- plus $30K from 35 others
Across 311 payments — averaging $5128.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$947K
- Bayer$169K
- Mirati Therapeutics, Inc.$157K
- Pfizer$144K
- Merck$77K
- Jazz Pharmaceuticals Inc.$53K
- plus $46K from 5 others
What the payments were for
- Consulting fees$50,20445%
- Speaking & faculty fees$44,99440%
- Travel & lodging$10,3979%
- Food & beverage$5,8495%
- Education$7871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $37,104 |
| AstraZeneca | 27 | $11,670 |
| Ipsen Biopharmaceuticals, Inc | 10 | $10,063 |
| Lilly USA, LLC | 3 | $9,225 |
| Array Biopharma Inc | 9 | $8,011 |
| Seagen Inc. | 14 | $5,691 |
| Novartis | 7 | $5,417 |
| Exelixis Inc. | 26 | $3,884 |
| Sanofi | 2 | $2,844 |
| Daiichi Sankyo Inc. | 15 | $2,729 |
| Bayer | 6 | $2,406 |
| Fresenius Kabi USA, LLC | 1 | $2,250 |
| Astellas Pharma US Inc | 6 | $2,142 |
| Jazz Pharmaceuticals Inc. | 1 | $2,108 |
| Mirati Therapeutics, Inc. | 4 | $1,552 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,531 |
| Taiho Oncology, Inc. | 2 | $1,114 |
| Tersera Therapeutics LLC | 17 | $443 |
| Genmab U.S., Inc. | 10 | $305 |
| GSK | 7 | $261 |
| Gilead | 10 | $238 |
| E.r. Squibb & Sons, L.L.C. | 10 | $178 |
| Merck | 9 | $164 |
| Eisai Inc. | 6 | $129 |
| Pfizer | 7 | $119 |
| AbbVie | 5 | $98 |
| CTI Biopharma Corp. | 3 | $74 |
| Rigel Pharmaceuticals, Inc. | 1 | $69 |
| Genentech USA, Inc. | 3 | $55 |
| Bristol Myers Squibb | 2 | $55 |
| Genentech, Inc. | 1 | $53 |
| Histosonics, Inc. | 1 | $37 |
| Boehringer Ingelheim | 2 | $36 |
| Caris MPI, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Sobi, Inc | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Clovis Oncology, Inc. | 2 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Novocure Inc. | 1 | $20 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,231 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 27 | $396,139 |
| OrserduElacestrant Hcl | 15 | $312,251 |
| EliquisApixaban | 232 | $188,936 |
| JakafiRuxolitinib Phosphate | 14 | $137,473 |
| XareltoRivaroxaban | 134 | $126,410 |
| Imatinib Mesylate | 41 | $51,573 |
| ZenpepLipase/Protease/Amylase | 15 | $36,175 |
| Fondaparinux Sodium | 11 | $7,882 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 39 | $6,720 |
| Enoxaparin Sodium | 15 | $2,911 |
| Scopolamine | 15 | $2,841 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $1,821 |
| Ondansetron OdtOndansetron | 92 | $1,566 |
| Hydroxyurea | 75 | $1,561 |
| Oxycodone Hcl | 88 | $1,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $119 | $585,075259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.